Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial.

Xiaojian QinDongmei JiWeijie GuWeiqing HanHong LuoChuanjun DuQing ZouZhongquan SunChaohong HeShaoxing ZhuTie ChongXin YaoBen WanXinfeng YangAobing BaiChunlei JinJianjun ZouDingwei Ye

Published in: BMC medicine (2022)

Clinical trials.gov NCT02691975; registered February 25, 2016.

Keyphrases

clinical trial
phase ii
phase iii
study protocol
open label
double blind
placebo controlled